UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis

Microbiology spectrum, 2023-12, Vol.11 (6), p.e0237123-e0237123

2023

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection

Clinical microbiology and infection, 2022-03, Vol.28 (3), p.447.e1-447.e6

2022

Link zum Volltext

Verfügbarkeit prüfen

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

Infection and drug resistance, 2018-01, Vol.11, p.1309-1320

2018

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Microbiology spectrum, 2024-04, Vol.12 (4), p.e0383623-e0383623

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015

European journal of clinical microbiology & infectious diseases, 2018-09, Vol.37 (9), p.1653-1659

2018

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France

JAC-antimicrobial resistance, 2021-06, Vol.3 (2), p.dlab081-dlab081

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Antimicrobial agents and chemotherapy, 2019-01, Vol.63 (1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates

Journal of antimicrobial chemotherapy, 2019-12, Vol.74 (12), p.3453-3461

2019

Link zum Volltext

Verfügbarkeit prüfen

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

BMC infectious diseases, 2019-02, Vol.19 (1), p.195-12, Article 195

2019

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain

Journal of global antimicrobial resistance., 2021-09, Vol.26, p.292-300

2021

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy

Journal of global antimicrobial resistance., 2021-06, Vol.25, p.390-398

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Journal of global antimicrobial resistance., 2024-09, Vol.38, p.71-82

2024

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

Journal of global antimicrobial resistance., 2021-12, Vol.27, p.1-11

2021

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)

JAC-antimicrobial resistance, 2022-04, Vol.4 (2), p.dlac030-dlac030

2022

Link zum Volltext

Verfügbarkeit prüfen

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Journal of global antimicrobial resistance., 2022-03, Vol.28, p.12-17

2022

Link zum Volltext

Verfügbarkeit prüfen

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

Open forum infectious diseases, 2023-07, Vol.10 (7), p.ofad329-ofad329

2023

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0110022-e0110022

2022

Link zum Volltext

Verfügbarkeit prüfen

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

Clinical microbiology and infection, 2021-05, Vol.27 (5), p.671-686

2021

Link zum Volltext

Verfügbarkeit prüfen

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S611-S614

2021

Link zum Volltext

Verfügbarkeit prüfen

1678. Activity of mecillinam against urinary tract clinical isolates from the United States during 2017-2020 including isolates resistant to comparator antibiotics and multi-drug resistant isolates

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

Journal of antimicrobial chemotherapy, 2022-09, Vol.77 (10), p.2895-2896

2022

Link zum Volltext

Verfügbarkeit prüfen

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S796-S796

2021

Link zum Volltext

Verfügbarkeit prüfen

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S798-S798

2021

Link zum Volltext

Verfügbarkeit prüfen

Study of the glucoamylase promoter in Aspergillus niger using green fluorescent protein

Microbiology (Society for General Microbiology), 1999-03, Vol.145 ( Pt 3), p.729

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Infectious Diseases
(16)
Microbiology
(16)
Pharmacology & Pharmacy
(11)
Cefiderocol
(10)
Humans
(9)
Anti-Bacterial Agents - Pharmacology
(8)
Cephalosporins - Pharmacology
(8)
Microbial Sensitivity Tests
(8)
Gram-Negative Bacteria
(6)
Anti-Bacterial Agents - Therapeutic Use
(4)
Antimicrobial Resistance
(4)
Carbapenem Resistance
(4)
Cephalosporins
(4)
Drug Resistance, Multiple, Bacterial
(4)
Methicillin
(4)
Mortality
(4)
Pneumonia
(4)
Poster Abstracts
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis

In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)

In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019

1678. Activity of mecillinam against urinary tract clinical isolates from the United States during 2017-2020 including isolates resistant to comparator antibiotics and multi-drug resistant isolates

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)

Study of the glucoamylase promoter in Aspergillus niger using green fluorescent protein

Suchergebnisse filtern